Immune parameters affecting adenoviral vector gene therapy in the brain

Area of Science:

• Oncology
• Gene Therapy
• Neuroscience

Background:

• Gene therapy using adenoviral vectors is a potential treatment for brain tumors.
• Systemic administration faces challenges due to anti-vector immune responses limiting transgene expression duration.
• The impact of immune responses on adenoviral vector efficacy within the central nervous system (CNS) is not fully understood.

Purpose of the Study:

• To investigate the duration of transgene expression following adenoviral vector administration in the CNS.
• To evaluate the effect of prior adenoviral exposure on subsequent vector administration within the CNS.
• To assess whether systemic anti-adenoviral immune responses impact CNS gene therapy.

Main Methods:

• Intravenous and intracerebral administration of a beta-galactosidase expressing adenoviral vector (Ad.CMV-betagal) in a preclinical model.
• Measurement of beta-galactosidase activity in systemic sites and the CNS over time.
• Rechallenge experiments with adenoviral vectors after initial administration.

Main Results:

• Maximal transgene expression in systemic sites (liver) peaked at day 4 and declined by day 7.
• Significant transgene expression persisted in the CNS for over 28 days after a single intracerebral injection.
• Repeat systemic vector administration was ineffective due to immunity, but intracerebral expression remained unaffected by prior exposure.

Conclusions:

• Adenoviral vector-mediated gene expression is significantly prolonged within the CNS compared to systemic sites.
• The immunoprivileged environment of the CNS appears to attenuate systemic anti-adenoviral immune responses.
• These findings suggest that CNS gene therapy for brain tumors may be less hindered by immune responses than systemic applications.